AbCellera Biologics (STU:8QQ) Total Stockholders Equity : €1,039.52 Mil (As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is AbCellera Biologics Total Stockholders Equity?

AbCellera Biologics's Total Stockholders Equity for the quarter that ended in Mar. 2024 was €1,039.52 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. AbCellera Biologics's Book Value per Share for the quarter that ended in Mar. 2024 was €3.54. The ratio of a company's debt over equity can be used to measure how leveraged this company is. AbCellera Biologics's Debt-to-Equity for the quarter that ended in Mar. 2024 was 0.07.

AbCellera Biologics Total Stockholders Equity Historical Data

The historical data trend for AbCellera Biologics's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AbCellera Biologics Total Stockholders Equity Chart

AbCellera Biologics Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Stockholders Equity

Get a 7-Day Free Trial

9.23

682.68

907.77

1,164.21

1,056.68

AbCellera Biologics Quarterly Data
	Dec18	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Stockholders Equity	Get a 7-Day Free Trial															1,128.74	1,102.83	1,108.26	1,056.68	1,039.52

AbCellera Biologics (STU:8QQ) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

AbCellera Biologics's Book Value per Share for the quarter that ended in Mar. 2024 is

Book Value per Share	=	(Total Stockholders Equity	-	Preferred Stock)	/	Shares Outstanding (EOP)
	=	(1039.52	-	0)	/	293.621
	=	3.54

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

AbCellera Biologics's Debt-to-Equity for the quarter that ended in Mar. 2024 is

Debt-to-Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(5.089	+	62.633)	/	1039.52
	=	0.07

AbCellera Biologics Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of AbCellera Biologics's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

AbCellera Biologics (STU:8QQ) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AbCellera Biologics Inc (STU:8QQ) » Definitions » Total Stockholders Equity

Comparable Companies

Traded in Other Exchanges

ABCL:USA

Address

2215 Yukon Street, Vancouver, BC, CAN, V5Y 0A1

Website

https://www.abcellera.com

AbCellera Biologics Inc is an antibody discovery and development engine that's specifically designed to address the barriers of conventional discovery, finding the optimal clinical candidate with greater precision and speed, getting to the clinic and patients sooner. With the integrated AbCellera platform, the company's experts search a wide range of diverse antibodies to select the most effective and developable leads fast and set partners up for enduring success. The company have extensive experience forging partnerships with emerging biotechs and leading pharmaceutical companies. AbCellera leverages proprietary hardware, software, and tools along with the latest data science, to operate as strategic partners and help develop optimized solutions faster for any program.

AbCellera Biologics (STU:8QQ) Headlines

No Headlines